B. Metzler Seel. Sohn & Co. Ag Halozyme Therapeutics, Inc. Transaction History
B. Metzler Seel. Sohn & Co. Ag
- $9.53 Billion
- Q4 2024
A detailed history of B. Metzler Seel. Sohn & Co. Ag transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, B. Metzler Seel. Sohn & Co. Ag holds 23,096 shares of HALO stock, worth $1.41 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
23,096
Previous 33,183
30.4%
Holding current value
$1.41 Million
Previous $1.9 Million
41.83%
% of portfolio
0.01%
Previous 0.02%
Shares
6 transactions
Others Institutions Holding HALO
# of Institutions
550Shares Held
124MCall Options Held
668KPut Options Held
259K-
Black Rock Inc. New York, NY17.6MShares$1.07 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.3MShares$810 Million0.01% of portfolio
-
State Street Corp Boston, MA7.18MShares$438 Million0.01% of portfolio
-
Snyder Capital Management L P San Francisco, CA4.17MShares$254 Million4.34% of portfolio
-
Bank Of America Corp Charlotte, NC3.45MShares$210 Million0.01% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $8.49B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...